• Content
  • Search
  • Navigation
  • Sitemap
  • About us
    • About us
    • Who we are
    • Our model
    • Data driven investment process
    • Our purpose, culture and values
    • Our history
  • Our people
    • Our people
    • Board of directors
  • Portfolio
    • Portfolio
    • Cell therapy
      • Overview
      • Autolus
      • Achilles Therapeutics
      • Quell Therapeutics
      • Resolution Therapeutics
      • Neogene Therapeutics
      • Clade Therapeutics
    • Gene therapy
      • Overview
      • Freeline Therapeutics
      • SwanBio Therapeutics
      • Purespring Therapeutics
    • Biologics
      • Overview
      • Anaveon
    • Small molecule
      • Overview
      • OMass Therapeutics
    • Previous investments
      • Overview
      • Gyroscope Therapeutics
      • Blue Earth
      • Nightstar
      • 14MG
      • Azeria Therapeutics
  • Sustainability
    • Sustainability
    • Message from Chief Executive, SIML
    • Our approach to sustainability reporting
    • Our social impact
    • Responsible investor and partner
      • Overview
      • Responsible investment process
      • A responsible partner
      • Sustainability within the Syncona portfolio
    • Inspiring and empowering our people
    • Responsible and ethical business
      • Overview
      • Environment
      • Syncona TCFD disclosure
    • Syncona’s approach to charity
      • Overview
      • The Syncona Foundation
    • Sustainability policies
  • News and Insights
  • Investors
    • Investors
    • Investment proposition
    • KPIs
    • Results and presentations
    • RNS and inside information
    • Share price centre
    • Governance
      • Overview
      • Our Committees
      • How we communicate with our stakeholders
    • Regulatory publications
    • Financial calendar
    • Analysts and advisers
    • Shareholder information
      • Overview
      • Shareholder documents
    • FAQs
  • Contact

News

Show
  • Sustainability
  • Financial
  • Operating News
news from
  • all companies
  • Syncona
  • all Cell therapy companies
  • Autolus
  • Achilles Therapeutics
  • Quell Therapeutics
  • Resolution Therapeutics
  • Neogene Therapeutics
  • Clade Therapeutics
  • all Gene therapy companies
  • Freeline Therapeutics
  • SwanBio Therapeutics
  • Purespring Therapeutics
  • all Biologics companies
  • Anaveon
  • all Small molecule companies
  • OMass Therapeutics
09.06.22

Anaveon Announces FDA Safe to proceed letter for Investigational New Drug (IND) Application for its no-alpha IL-2 agonist, ANV419

  • Operating News
  • Biologics
  • Anaveon
11.04.22

Anaveon presents compelling data from the Phase I/II study of ANV419 during the AACR Annual Meeting 2022

  • Biologics
  • Anaveon
09.03.22

Anaveon to present first clinical data from the Phase I/II study of ANV419 at the AACR Annual Meeting 2022

  • Operating News
  • Biologics
  • Anaveon
15.12.21

Anaveon to raise CHF 110 million in oversubscribed Series B financing

  • Biologics
  • Anaveon
12.11.21

Anaveon announces poster presentation at the 2021 Society for Immunotherapy of Cancer Annual Meeting

  • Biologics
  • Anaveon
24.06.21

Anaveon doses first patient in a Phase I/II study to evaluate the safety, dosing and clinical activity of ANV419 in patients with solid tumors

  • Operating News
  • Biologics
  • Anaveon
Load more

Sign-up for company news alerts

Get the latest RNS, company news, share price information and results from Syncona

  • RNS alerts
  • Company alerts

Syncona Investment Management Limited
2nd Floor
8 Bloomsbury Street
London
WC1B 3SR
contact@synconaltd.com

  • About us
  • Our people
  • Portfolio
  • Sustainability
  • News and Insights
  • Investors
  • Contact
  • Copyright © Syncona 2022
  • Accessibility
  • Privacy & cookies
  • Employee privacy notice
  • Third party privacy notice
  • Regulatory publications
  • Modern Slavery Statement

Syncona Limited is registered in Guernsey no. 55514, registered office Arnold House, PO Box 273, St Julian’s Avenue, St Peter Port, Guernsey GY1 3RD.
Syncona Investment Management Limited is registered in England no. 10497864, 8 Bloomsbury Street, London WC1B 3SR and is authorised and regulated by the FCA. Syncona Limited is managed by Syncona Investment Management Limited.

Designed & built by SampsonMay
  • About us
    • About us
    • Who we are
    • Our model
    • Data driven investment process
    • Our purpose, culture and values
    • Our history
  • Our people
    • Our people
    • Board of directors
  • Portfolio
    • Portfolio
    • Cell therapy
      • Overview
      • Autolus
      • Achilles Therapeutics
      • Quell Therapeutics
      • Resolution Therapeutics
      • Neogene Therapeutics
      • Clade Therapeutics
    • Gene therapy
      • Overview
      • Freeline Therapeutics
      • SwanBio Therapeutics
      • Purespring Therapeutics
    • Biologics
      • Overview
      • Anaveon
    • Small molecule
      • Overview
      • OMass Therapeutics
    • Previous investments
      • Overview
      • Gyroscope Therapeutics
      • Blue Earth
      • Nightstar
      • 14MG
      • Azeria Therapeutics
  • Sustainability
    • Sustainability
    • Message from Chief Executive, SIML
    • Our approach to sustainability reporting
    • Our social impact
    • Responsible investor and partner
      • Overview
      • Responsible investment process
      • A responsible partner
      • Sustainability within the Syncona portfolio
    • Inspiring and empowering our people
    • Responsible and ethical business
      • Overview
      • Environment
      • Syncona TCFD disclosure
    • Syncona’s approach to charity
      • Overview
      • The Syncona Foundation
    • Sustainability policies
  • News and Insights
  • Investors
    • Investors
    • Investment proposition
    • KPIs
    • Results and presentations
    • RNS and inside information
    • Share price centre
    • Governance
      • Overview
      • Our Committees
      • How we communicate with our stakeholders
    • Regulatory publications
    • Financial calendar
    • Analysts and advisers
    • Shareholder information
      • Overview
      • Shareholder documents
    • FAQs
  • Contact
GBX 201.50
Change: -3.00 (-1.47%)

Search